Hancock Whitney’s Akcea Therapeutics Inc AKCA Stock Holding History

Hancock Whitney’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16,481	Closed	-$226K	–	843
2020 Q2	$226K	Buy	+16,481	New	+$254K	0.01%	683

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hancock Whitney's AKCA Position: Q3 2020 in Review

Hancock Whitney sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 16,481 shares — an estimated $226K sold.

Hancock Whitney first reported a position in AKCA in Q2 2020 and held it in 1 quarter. The position peaked at $226K in Q2 2020. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

Hancock Whitney reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
Hancock Whitney sold 16,481 Akcea Therapeutics Inc shares in Q3 2020, an estimated $226K.
Hancock Whitney first reported a position in Akcea Therapeutics Inc in Q2 2020 and held it in 1 quarter.
Hancock Whitney's Akcea Therapeutics Inc position peaked at $226K in Q2 2020.
98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Hancock Whitney's 13F filing for Q3 2020, filed 5 Nov 2020.